Doug Janzen

Has been involved in the Life Sciences industry for the past 19 years.

Currently the Founder and President of Northview Ventures, an organization that invests in and provides strategic advisory services to a number of technology companies.

President and CEO of Cardiome Pharma, a NASDAQ-listed drug development company that raised over $300 million from investors, and completed over $1 billion in licensing deals during his tenure. In 2010, Cardiome’s lead product, Brinavess, was approved and launched in Europe by Merck.

An investment banker with Cormark Securities, acting as Managing Director of Life Sciences.

Past Chair of LifeSciences BC, has served as a Director with Biotech Canada and currently sits as a Director on a number of public and private boards.

A past winner of Business in Vancouver’s Top 40 Under 40 Award.